GLP-3 + Cagri
Typical Dosing Protocols (Research/Compounded Use Only) – Retatrutide + Cagrilintide (Stack)
Common protocol:
Retatrutide: Start at 1–2 mg subcutaneously once weekly, titrate every 4 weeks up to 8–12 mg weekly.
Cagrilintide: Start at 0.6 mg subcutaneously once weekly, titrate every 2–4 weeks up to 2.4–4.5 mgweekly.
Both peptides are typically injected on the same day each week (e.g., Monday morning).
Other reported ranges:
Retatrutide: 4–12 mg weekly (most common maintenance 8–12 mg)
Cagrilintide: 2.4–4.5 mg weekly
Many users combine 8 mg Retatrutide + 2.4 mg Cagrilintide or 12 mg Retatrutide + 4.5 mg Cagrilintidefor aggressive fat loss.
Reconstitution example:
Retatrutide (10–20 mg vial): Add 2 mL bacteriostatic water.
Cagrilintide (5–10 mg vial): Add 2 mL bacteriostatic water.
Draw both into the same insulin syringe for a single weekly injection.
Administration: Subcutaneous injection (abdomen, thigh, or upper arm). Slow titration is strongly recommended to minimize GI side effects.
Dosing is highly individualized based on goals, tolerance, and response—consult a qualified healthcare provider experienced with incretin therapies for personalized guidance. This is for informational purposes only.
